Drugs / pegylated liposomal doxorubicin hydrochloride
last change 23 days ago re-read 3 minutes ago

pegylated liposomal doxorubicin hydrochloride

also known as PLD · doxil · Lipodox · Liposomal Doxorubicin
Developed for
primary peritoneal carcinoma · fallopian tube carcinoma · ovarian carcinoma · female breast carcinoma · plasma cell myeloma · male breast carcinoma · metastatic malignant neoplasm · ovarian clear cell cystadenocarcinoma
+30 more · ovarian endometrioid adenocarcinoma · ovarian serous cystadenocarcinoma · triple-negative breast carcinoma · undifferentiated ovarian carcinoma · cervical cancer · colorectal carcinoma · endometrial cancer · fallopian tube cancer · HER2 positive breast carcinoma · Kaposi's sarcoma · lymphoma · ovarian Brenner tumor · ovarian cancer · ovarian mucinous cystadenocarcinoma · ovarian seromucinous carcinoma · plasma cell leukemia · uterine corpus cancer · fallopian tube carcinosarcoma · fallopian tube clear cell adenocarcinoma · fallopian tube endometrioid adenocarcinoma · fallopian tube mucinous adenocarcinoma · fallopian tube serous adenocarcinoma · fallopian tube transitional cell carcinoma · ovarian carcinosarcoma · ovarian clear cell adenocarcinoma · ovarian mucinous adenocarcinoma · ovarian serous adenocarcinoma · ovarian transitional cell carcinoma · primary peritoneal serous adenocarcinoma · sarcoma
Investigated by
National Cancer Institute (NCI) · Gynecologic Oncology Group · City of Hope Medical Center · M.D. Anderson Cancer Center · Ortho Biotech, Inc. · University of Washington
+11 more · Herbert Irving Comprehensive Cancer Center · Mayo Clinic · Medical Research Council · Merck Sharp & Dohme LLC · Millennium Pharmaceuticals, Inc. · Oncotherapeutics · Rutgers Cancer Institute of New Jersey · Rutgers, The State University of New Jersey · SWOG Cancer Research Network · The University of Texas Health Science Center, Houston · UNC Lineberger Comprehensive Cancer Center

Trials 20

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT03203525 Jun 2020 → Dec 2026 expected colorectal carcinoma, metastatic malignant neoplasm M.D. Anderson Cancer Center Active not recruiting No outcome recorded
Phase 1 NCT03591744 Oct 2018 → Oct 2019 plasma cell leukemia City of Hope Medical Center Withdrawn No outcome recorded
Phase 1 NCT01970722 May 2014 → Jan 2027 expected fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma, uterine corpus cancer City of Hope Medical Center Active not recruiting No outcome recorded
Phase 1 NCT01489371 Jul 2012 → Dec 2014 fallopian tube carcinoma, ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian seromucinous carcinoma +3 Gynecologic Oncology Group Completed No outcome recorded
Phase 1 NCT01294293 Mar 2011 → Jul 2014 fallopian tube carcinoma, ovarian Brenner tumor, ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma +4 Gynecologic Oncology Group Completed No outcome recorded
Phase 1 NCT01145430 Jun 2010 → May 2017 fallopian tube carcinoma, male breast carcinoma, ovarian carcinoma, primary peritoneal carcinoma +1 National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00744354 Oct 2008 → Dec 2011 plasma cell myeloma UNC Lineberger Comprehensive Cancer Center Terminated No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT00849251 Nov 2008 → Dec 2011 plasma cell myeloma University of Washington Terminated No outcome recorded
Phase 1/2 NCT00334932 Feb 2006 → Jan 2010 plasma cell myeloma Herbert Irving Comprehensive Cancer Center Unknown No outcome recorded
Phase 1/2 NCT00331552 Feb 2006 → Feb 2011 HER2 positive breast carcinoma, male breast carcinoma University of Washington Completed No outcome recorded
Phase 1/2 NCT00182767 Jan 2006 → Apr 2012 fallopian tube cancer, female breast carcinoma, ovarian carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 27 trials
Phase 2 NCT03907475 Jul 2019 → Jun 2027 expected metastatic malignant neoplasm National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 2 NCT02312245 Jul 2015 → Apr 2023 fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma Mayo Clinic Completed No outcome recorded
Phase 2 NCT02315196 Feb 2015 → Feb 2021 overdue female breast carcinoma, triple-negative breast carcinoma Rutgers, The State University of New Jersey Active not recruiting No outcome recorded
Phase 2 NCT00742404 Jul 2008 → Jul 2010 plasma cell myeloma Oncotherapeutics Unknown No outcome recorded
Phase 2 NCT00101010 Sep 2005 → Sep 2014 lymphoma M.D. Anderson Cancer Center Completed No outcome recorded
Phase 2 NCT00004888 Jan 2001 → Apr 2008 female breast carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00003135 Nov 1997 → Sep 2009 cervical cancer, endometrial cancer, female breast carcinoma, ovarian cancer The University of Texas Health Science Center, Houston Unknown No outcome recorded
Phase 32 trials
Phase 3 NCT00011986 Jan 2001 → Mar 2010 ovarian carcinoma, primary peritoneal carcinoma Gynecologic Oncology Group Completed No outcome recorded
Phase 3 NCT00003350 Mar 1999 → Mar 2007 Kaposi's sarcoma National Cancer Institute (NCI) Completed No outcome recorded
Comparator or background therapy6 trials
Phase 1 NCT01281514 Background Dec 2010 → Jan 2018 fallopian tube cancer, malignant epithelial tumor of ovary, peritoneum cancer Fox Chase Cancer Center Completed No outcome recorded
Phase 1 NCT01673217 Background Apr 2009 → Oct 2011 fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma Roswell Park Cancer Institute Completed No outcome recorded
Phase 2 NCT07504588 Comparator Sep 2026 → Apr 2029 expected fallopian tube endometrioid adenocarcinoma, fallopian tube serous adenocarcinoma, ovarian endometrioid adenocarcinoma, primary peritoneal serous adenocarcinoma National Cancer Institute (NCI) Not yet recruiting No outcome recorded
Phase 2 NCT02364713 Comparator Mar 2015 → Jan 2022 fallopian tube carcinosarcoma, fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma +11 Mayo Clinic Terminated No outcome recorded Stop: Enrollment
Phase 3 NCT00992706 Background Sep 2009 → Aug 2011 breast cancer, hand-foot syndrome Swiss Cancer Institute Completed Missed primary

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 27 sources stand behind the page.

FieldValueCited text
Known as Pegylated Liposomal Doxorubicin Hydrochloride ClinicalTrials.gov intervention name — accepted as the source's own label NCT01145430 ↗
25

NCT02312245 ↗

NCT01970722 ↗

NCT02364713 ↗

NCT00003135 ↗

NCT03907475 ↗

NCT00003350 ↗

NCT00744354 ↗

NCT02315196 ↗

NCT01673217 ↗

NCT01281514 ↗

Show 15 more sources

Known as doxil “Liposomal Doxorubicin (Doxil®)/ Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma” NCT00334932 ↗
1

“neoadjuvant pegylated liposomal doxorubicin hydrochloride (doxil) and carboplatin” NCT02315196 ↗

Known as Lipodox “pegylated liposomal doxorubicin hydrochloride (PLD; Doxil; Lipodox)” NCT01489371 ↗
Known as Liposomal Doxorubicin “Liposomal Doxorubicin (Doxil®)/ Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma” NCT00334932 ↗
Known as PLD “Drugs used in chemotherapy, such as carboplatin and pegylated liposomal doxorubicin hydrochloride (PLD) work in different ways to stop the growth of tumor cells, either by...” NCT01281514 ↗
2

“ixabepilone plus pegylated liposomal doxorubicin (PLD) in patients with advanced taxane-pretreated ovarian and breast cancer.” PMID 20357034 ↗ Mar 2010

“pegylated liposomal doxorubicin hydrochloride (PLD; Doxil; Lipodox)” NCT01489371 ↗

Action Inhibit “Drugs used in chemotherapy, such as, dexamethasone, pegylated liposomal doxorubicin hydrochloride, and lenalidomide, work in different ways to stop the growth of cancer cells” NCT03591744 ↗
Route Intravenous “doxorubicin HCl liposome IV over 30 minutes on day 6” NCT00003135 ↗